Literature DB >> 32154908

Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data.

Celestia S Higano1,2, Andrew J Armstrong3, Oliver Sartor4, Nicholas J Vogelzang5, Philip W Kantoff6, David G McLeod7, Christopher M Pieczonka8, David F Penson9, Neal D Shore10, Jeffrey Vacirca11, Raoul S Concepcion12, Ronald F Tutrone13, Luke T Nordquist14, David I Quinn15, Vahan Kassabian16, Mark C Scholz17, Matt Harmon18, Robert C Tyler18, Nancy N Chang18, Hong Tang18, Matthew R Cooperberg19.   

Abstract

Entities:  

Year:  2020        PMID： 32154908      PMCID： PMC7935468          DOI： 10.1002/cncr.32785

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  3 in total

1.  Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data.

Authors:  Graça M Dores; Manette T Niu; Hector S Izurieta
Journal:  Cancer       Date:  2020-03-10       Impact factor: 6.860

2.  Adverse Events Associated With the Use of Sipuleucel-T Reported to the US Food and Drug Administration's Adverse Event Reporting System, 2010-2017.

Authors:  Graça M Dores; Marthe Bryant-Genevier; Silvia Perez-Vilar
Journal:  JAMA Netw Open       Date:  2019-08-02

3.  Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer.

Authors:  Celestia S Higano; Andrew J Armstrong; A Oliver Sartor; Nicholas J Vogelzang; Philip W Kantoff; David G McLeod; Christopher M Pieczonka; David F Penson; Neal D Shore; Jeffrey Vacirca; Raoul S Concepcion; Ronald F Tutrone; Luke T Nordquist; David I Quinn; Vahan Kassabian; Mark C Scholz; Matt Harmon; Robert C Tyler; Nancy N Chang; Hong Tang; Matthew R Cooperberg
Journal:  Cancer       Date:  2019-09-04       Impact factor: 6.860
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.